A Single Arm Open Label Study to Determine the Safety and Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Recurrence of Glioma in Patients Who Received a Prior Treatment With 186RNL

This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who received a prior treatment of 186RNL.

开始日期2024-12-12

申办/合作机构

Plus Therapeutics, Inc.

NCT05034497

/ Active, not recruiting临床1期

A Multicenter Phase 1 Clinical Study to Determine the Maximum Tolerated Dose/Maximum Feasible Dose, Safety,& Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered Via Intraventricular Catheter for Leptomeningeal Metastases

This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).

开始日期2021-12-06

申办/合作机构

Plus Therapeutics, Inc.

NCT01906385

/ Recruiting临床1/2期

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)

This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL.

开始日期2015-06-03

申办/合作机构

Plus Therapeutics, Inc.

[+1]

100 项与 Retreatment Rhenium Liposome 相关的临床结果

登录后查看更多信息

100 项与 Retreatment Rhenium Liposome 相关的转化医学

登录后查看更多信息

100 项与 Retreatment Rhenium Liposome 相关的专利（医药）

登录后查看更多信息

项与 Retreatment Rhenium Liposome 相关的文献（医药）

2012-09-04·Molecular Pharmaceutics2区 · 医学

Feasibility of Eradication of Breast Cancer Cells Remaining in Postlumpectomy Cavity and Draining Lymph Nodes following Intracavitary Injection of Radioactive Immunoliposomes

2区 · 医学

Article

作者: Goins, Beth ; Phillips, William T. ; Bao, Ande ; Hrycushko, Brian A. ; Li, Shihong

Most diagnosed early stage breast cancer cases are treated by lumpectomy and adjuvant radiation therapy, which significantly decreases the locoregional recurrence but causes inevitable toxicity to normal tissue. By using a technique of preparing liposomes carrying technetium-99m ((99m)Tc), rhenium-186 ((186)Re), or rhenium-188 ((188)Re) radionuclides, as well as chemotherapeutic agents, or their combination, for cancer therapy with real time image-monitoring of pharmacokinetics and prediction of therapy effect, this study investigated the potential of a novel targeted focal radiotherapy with low systemic toxicity using radioactive immunoliposomes to treat both the surgical cavity and draining lymph nodes in a rat breast cancer xenograft positive surgical margin model. Immunoliposomes modified with either panitumumab (anti-EGFR) or bevacizumab (anti-VEGF) were remote loaded with (99m)Tc diagnostic radionuclide, and injected into the surgical cavity of female nude rats with positive margins postlumpectomy. Locoregional retention and systemic distribution of (99m)Tc-immunoliposomes were investigated by nuclear imaging, stereofluorescent microscopic imaging, and gamma counting. Histopathological examination of excised draining lymph nodes was performed. The locoregional retention of (99m)Tc-immunoliposomes in each animal was influenced by the physiological characteristics of the surgical site of individual animals. Panitumumab- and bevacizumab-liposome groups had higher intracavitary retention compared with the control liposome groups. Draining lymph node uptake was influenced by both the intracavitary radioactivity retention level and metastasis status. The panitumumab-liposome group had higher accumulation on the residual tumor surface and in the metastatic lymph nodes. Radioactive liposomes that were cleared from the cavity were metabolized quickly and accumulated at low levels in vital organs. Therapeutic radionuclide-carrying specifically targeted panitumumab- and bevacizumab-liposomes have increased potential compared to non-antibody targeted liposomes for postlumpectomy focal therapy to eradicate remaining breast cancer cells inside the cavity and draining lymph nodes with low systemic toxicity.

2008-01-01·Journal of Drug Targeting3区 · 医学

Imaging of¹⁸⁶Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis

3区 · 医学

Article

作者: Goins, Beth A. ; McMahan, C. Alex ; Bao, Ande ; McManus, Linda M. ; Zavaleta, Cristina L. ; Phillips, William T.

This study determined the biodistribution of rhenium-186 ((186)Re) encapsulated in biotin-liposomes containing patent blue dye, injected intraperitoneally (IP) with avidin in an OVCAR-3 ovarian cancer xenograft model and evaluated tumor response of this therapy with fluorine-18-fluorodeoxyglucose ((18)F-FDG) microPET imaging. Treated rats (n = 8) received an IP injection of (186)Re-blue-biotin-liposomes (1000 MBq/kg) 30 min before an IP injection of avidin (5 mg), whereas control rats (n = 4) received a sham IP injection of saline. Scintigraphic images showed that (186)Re-blue-biotin liposomes/avidin were retained in the peritoneal cavity with 18% of the original activity remaining after 5 days. From 1 to 4 weeks post-treatment, peritoneal (18)F-FDG standard uptake values decreased 30% in treatment group, yet increased 44% in control group. Total number of cells in ascites was significantly higher in control versus treatment group. Omental fat in control rats had numerous tumor cells compared with treated rats. Results show the potential for (186)Re-blue-biotin-liposome/avidin system in treating advanced ovarian cancer involving peritoneal carcinomatosis.

Journal of Nuclear Medicine

¹⁸⁶Re-liposome labeling using ¹⁸⁶Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats

作者: Goins, Beth ; Negrete, George ; Klipper, Robert ; Bao, Ande ; Phillips, William T.

Liposomes are important carriers for controlling the spatial and temporal distribution of drug mols. or other bioactive mols.Radiolabeled liposomes have potential applications in diagnostic imaging and radionuclide therapy.The purpose of this study was to develop a practical method for labeling liposomes with therapeutic rhenium radionuclides, using ¹⁸⁶Re as an example.Methods: An SNS pattern ligand, N,N-bis(2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA), and an S pattern ligand, benzene thiol (BT), were used to make 2 kinds of ¹⁸⁶Re-SNS/S complexes, ¹⁸⁶Re-BMEDA and ¹⁸⁶Re-BMEDA + BT.These ¹⁸⁶Re-SNS/S complexes were mixed with neutral liposomes encapsulating cysteine or (NH₄)₂SO₄ to prepare ¹⁸⁶Re-liposomes.The in vitro labeling stability of ¹⁸⁶Re-liposomes was investigated by incubation in 50% fetal bovine serum/50% phosphate-buffered saline, pH 7.4, at 37°C.Rat distribution studies of ¹⁸⁶Re-liposomes after i.v. injection were also performed.Results: The labeling efficiencies of ¹⁸⁶Re-liposomes were 52.9%-81.3% depending on the ¹⁸⁶Re-SNS/S complex chosen and whether cysteine- or (NH₄)₂SO₄-encapsulated liposomes were used.¹⁸⁶Re-(NH₄)₂SO₄ liposomes labeled with ¹⁸⁶Re-BMEDA had the best in vitro labeling stability in serum with 89.8% ± 3.1% of the radioactivity associated with liposomes at 24 h and 76.2% ± 5.1% at 96 h.A specific activity of 1.85 GBq (50 mCi) of ¹⁸⁶Re per 50 mg of phospholipid could be achieved with good labeling stability.Biodistributions were followed for 72 h and showed good in vivo stability for ¹⁸⁶Re-liposomes that was characterized by a slow blood clearance and a gradually increasing spleen accumulation.¹⁸⁶Re-BMEDA alone had fast blood clearance and no accumulation in spleen.Conclusion: A practical method for labeling liposomes with ¹⁸⁶Re using ¹⁸⁶Re-SNS/S complexes is described.The labeled ¹⁸⁶Re-liposomes were stable in serum and in vivo and could potentially be useful for radionuclide therapy.

项与 Retreatment Rhenium Liposome 相关的新闻（医药）

2025-04-23

·GlobeNewswire-Health Care

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company’s Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. “Kyle’s decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus’ board of directors,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “Furthermore, in his role as audit chair, Kyle will be a force in the successful execution of Plus’ ambitious business plan and driving stockholder value.” Mr. Guse is an executive with 30 years of professional experience leading the world’s most innovative companies. For over a decade he served as Chief Financial Officer, General Counsel and Secretary of Atossa Therapeutics, Inc., a NASDAQ-listed company developing a drug to prevent and treat breast cancer, which had previously developed and marketed medical devices, and that owned and operated a CLIA certified laboratory. Currently, he serves as Chief Legal Officer of DDC Enterprise Ltd., an NYSE-listed international consumer foods company. Formerly, he was a partner and practiced corporate law at several of the top international law firms. Prior to that, he was a Certified Public Accountant with a Big 4 accounting firm. He earned his J.D. (cum laude) from Santa Clara University Law School and an M.B.A. from California State University, Sacramento, where he also earned his Bachelor of Science degree. “Plus Therapeutics has multiple and significant opportunities in both the therapeutics and diagnostics markets with REYOBIQ™ (rhenium Re186 obisbemeda) and CNSide, and I believe it has tremendous potential to make an impact on the market,” said Mr. Guse. “I’m looking forward to collaborating closely with the Board and with management to help bring the Company to its full potential for stockholders, practitioners, and patients.” About Plus TherapeuticsHeadquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/. Cautionary Statement Regarding Forward-Looking StatementsThis press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential promise of REYOBIQ™, expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates; the Company’s clinical trials, including statements regarding the timing and characteristics of the ReSPECT-LM single dose and multi-dose clinical trials; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts. The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company’s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so. Investor ContactCORE IRinvestor@plustherapeutics.com

高管变更

2025-04-21

·GlobeNewswire-Health Care

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

April 15, 2025 -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the online availability of new data on its lead compound REYOBIQ™ (rhenium Re186 obisbemeda) in an abstract for both an oral presentation and a poster to be presented at the Nuclear Medicine and Neurooncology conference to be held May 9-10, 2025 in Vienna, Austria. The abstract, titled, “Rhenium Obisbemeda (REYOBIQ) in Leptomeningeal Metastases,” highlights additional data from the Company’s completed Phase 1 ReSPECT-LM dose escalation trial demonstrating a dose dependent increase in the average absorbed dose to the cranial and spinal subarachnoid space reaching 253Gy in Cohort 5. Neuroimaging response data was available for 16 patients as of the data cutoff with five of those (31%) showing a partial response. An additional seven patients showed stable disease by neuroimaging through day 112 for a Clinical Benefit Rate (complete response + partial response + stable disease) of 75%. Additionally, a clinical response based on the physician evaluation showed a decrease in disease findings in two of 14 evaluable patients (14%) and 10 patients showed stable findings through day 112 for an 86% Clinical Benefit Rate. Furthermore, there was no dose limiting toxicity (DLT) observed in the first four cohorts, with a grade 4 DLT (thrombocytopenia), one in each of Cohorts 5 and 6. Finally, RNA sequencing of LM cells showed early induction of apoptosis, with an innate immune response followed by an increase in T cells and an adaptive immune response by Day 28. Further details can be found here; the Company will provide additional data and explanation following the meeting. "This newly-presented ReSPECT-LM data further reinforces our confidence in the potential utility of REYOBIQ in these critically ill patients with the devastating diagnosis of Leptomeningeal Metastases," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Reyobiq can be delivered at very high doses of radiation to the cancer at the recommended phase 2 dose and shows promising response data across multiple parameters while simultaneously being well tolerated by normal organs and tissues." LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3-5% of breast cancer patients developing LM. Additionally, lung cancer, GI cancers and melanoma can also spread to the CSF and result in LM. LM occurs in approximately 5% of people with cancer and is usually terminal with 1-year and 2-year survival of just 7% and 3%, respectively. The incidence of LM is on the rise, partly because cancer patients are living longer and partly because many standard chemotherapies cannot reach sufficient concentrations in the spinal fluid to kill the tumor cells, yet there are no FDA-approved therapies specifically for LM patients, who often succumb to this complication within weeks to several months, if untreated. REYOBIQ™ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. REYOBIQ™ has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. REYOBIQ™ is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT). Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/. The content above comes from the network. if any infringement, please contact us to modify.

临床结果放射疗法ASCO会议

2025-03-07

·Pharmaceutical Technology

FDA ODD given to Plus Therapeutics’ injectable radiotherapy

The therapy is intended for LM in individuals with lung cancer. Credit: Jo Panuwat D/Shutterstock. The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Plus Therapeutics’ injectable radiotherapy, Rhenium ( 186 Re) Obisbemeda, for treating leptomeningeal metastases (LM) in lung cancer sufferers. The designation is awarded to drugs aimed at rare conditions (affecting fewer than 200,000 individuals in the US) and comes with benefits such as seven years of market exclusivity. The ODD for the therapy follows the completion of the single-dose Phase I ReSPECT-LM trial, which determined the recommended Phase II dose. Plus Therapeutics chief development officer Mike Rosol stated: “Receiving ODD for Rhenium ( 186 Re) Obisbemeda marks a significant milestone in our efforts to develop a much-needed therapy for lung cancer patients with leptomeningeal metastases. “This designation, in combination with our previously granted fast track designation, strengthens our pathway toward delivering an innovative, targeted radiotherapeutic solution for this highly underserved patient population.” Plus Therapeutics is currently progressing a Phase II single-dose expansion trial and a Phase I multiple-dose trial. The company is in discussions with the US regulator to establish the optimal pivotal trial strategy. A rare cancer complication, LM involves the spread of primary cancer to the cerebrospinal fluid and the leptomeninges around the spinal cord and brain. Designed to deliver targeted high-dose radiation to central nervous system (CNS) tumours, the therapy improves patient outcomes by offering a more potent radiation dose compared to existing therapies. The therapy is currently under assessment for recurrent glioblastoma and LM in the ReSPECT-GBM and ReSPECT-LM trials. Plus Therapeutics widened its collaboration with Piramal Pharma Solutions (PPS) in May 2023 to produce additional current good manufacturing practice liposome intermediate drug products .

快速通道孤儿药临床2期放射疗法临床结果

100 项与 Retreatment Rhenium Liposome 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑膜肿瘤	临床2期	-	Plus Therapeutics, Inc.	2023-10-10
复发性胶质瘤	临床2期	美国	Plus Therapeutics, Inc.	2015-06-03
复发性胶质母细胞瘤	临床2期	-	Plus Therapeutics, Inc.	-
软脑膜转移性恶性肿瘤	临床1期	美国	Plus Therapeutics, Inc.	2021-12-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05034497 (ReSPECT-LM, GlobeNewswire) 人工标引	临床1期	软脑膜转移性恶性肿瘤	20	Rhenium (186Re) Obisbemeda	(糧願壓範醖製餘蓋夢鹽) = 1 dose-limiting toxicity (thrombocytopenia) observed in Cohort 5. 淵廠蓋壓糧繭積獵鹹糧 (淵夢窪繭簾醖遞壓積鑰 )	积极	2024-11-25
NCT05034497 (ReSPECT-LM, GlobeNewswire) 人工标引	临床1期	软脑膜转移性恶性肿瘤	16	Rhenium (186Re) Obisbemeda	艱築築艱鹹願構選膚繭(繭壓鑰觸廠積築鹽憲衊) = 鹹鹽醖鬱夢積選憲壓衊窪廠願積製顧糧願醖選 (積積構淵蓋鏇壓鬱繭遞 ) 更多	积极	2024-08-12
NCT01906385 (ReSPECT-GBM, Corporate Publications) 人工标引	临床1/2期	复发性胶质母细胞瘤	15	186RNL	(製選襯鏇憲鹽積廠壓願) = 糧醖蓋襯壓鬱觸鑰艱鏇鹹淵齋製襯簾醖蓋鹽鏇 (齋鏇壓鹽選餘餘夢選鹹 ) 更多	积极	2023-11-20
NCT05034497 (ReSPECT-LM, NEWS) 人工标引	临床1/2期	脑膜肿瘤	10	186RNL	(醖鬱鹽膚選積鏇範夢衊) = 網顧網觸窪簾鏇襯衊襯糧膚襯選顧衊網艱憲獵 (遞糧廠築艱觸淵壓糧壓 ) 更多	积极	2023-08-11
NCT05034497 (ReSPECT-LM, Corporate Publications) 人工标引	临床1期	脑膜白血病	4	186RNL	(膚積醖廠襯鹹膚壓壓製) = 遞襯鏇窪憲餘齋淵夢鹹窪構觸構壓構網憲鑰觸 (壓簾顧願繭願膚遞淵壓 )	积极	2022-10-19
NCT01906385 (RESPECT, SNO2022) 人工标引	临床1期	复发性胶质瘤	21	186RNL	餘艱廠醖醖壓憲廠顧選(鹹膚築遞網鏇製糧鑰鹹) = patients not receiving prior bevacizumab was 75% vs. 48% in those that had. 積夢繭鏇憲糧遞構觸築 (獵遞簾獵糧鹹願築窪淵 ) 更多	积极	2022-08-05
NCT05034497 (ReSPECT-LM, SNO2022) 人工标引	临床1/2期	脑膜白血病	1	186RNL	(艱顧觸壓壓壓蓋醖範鬱) = The dose was well-tolerated with no complaints/AEs as of Day 28 following treatment 齋餘築選鏇製壓壓鏇築 (鏇獵網鏇鏇顧鏇糧衊繭 )	积极	2022-08-05
NCT05034497 (SNMMI2022) 人工标引	临床1/2期	胶质母细胞瘤	24	186RNL	(憲衊遞選觸構範鹹鹹繭) = 鬱鏇遞製淵積糧積壓築繭憲醖衊繭製鏇製鏇憲 (構顧築膚築願繭餘淵糧 ) 更多	积极	2022-06-19
ASCO2004	临床2期	转移性去势抵抗性前列腺癌	-	High activity rhenium-186 hydroxyethylidene diphosphonate (HEDP) with autologous peripheral blood stem cell (PBSC) transplant	憲鏇齋淵積範鹹範夢獵(艱廠獵範鬱廠網顧艱鹽) = 齋顧鹽顧廠獵餘鹹範鏇遞淵蓋鬱範艱艱膚構鏇 (窪鹹餘膚範衊鏇繭顧艱 ) 更多	-	2004-07-15